Literature DB >> 8864752

Intra- and extracellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody.

J D Chen1, Q Yang, A G Yang, W A Marasco, S Y Chen.   

Abstract

Recently, we developed a novel anti-HIV-1 approach by transducing an anti-gp120 antibody gene into lymphocytes, resulting in the resistance to HIV-1 infection by the combined intra- and extracellular binding activities of the neutralizing antibody. To extend this study, we improved the co-expression of the heavy and light chains of the Fab105 fragment of the anti-gp120 antibody F105 by using an internal ribosome entry site (IRES) sequence. The Fab105 expression cassette was then cloned into an adeno-associated virus (AAV) shuttle vector, and encapsidated recombinant AAV-Fab105 vectors were produced. The Fab105 antibody gene was shown to be transduced into human lymphocytes by using the recombinant AAV viruses. The transduced lymphocytes were able to produce and secrete the Fab105 fragments, while maintaining their normal morphology, growth rates, and responsiveness to mitogen stimulation. The infection of several primary HIV-1 patient isolates was effectively blocked in the transduced lymphocytes. This study indicates that the combined intra- and extracellular immunization approach may be useful for the treatment of HIV-1-infected patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8864752     DOI: 10.1089/hum.1996.7.13-1515

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  10 in total

Review 1.  Research and development of next generation of antibody-based therapeutics.

Authors:  Jing Li; Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

2.  Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection.

Authors:  A G Yang; X Bai; X F Huang; C Yao; S Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

3.  Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization.

Authors:  Wentao Gao; Adam C Soloff; Xiuhua Lu; Angela Montecalvo; Doan C Nguyen; Yumi Matsuoka; Paul D Robbins; David E Swayne; Ruben O Donis; Jacqueline M Katz; Simon M Barratt-Boyes; Andrea Gambotto
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Design and intracellular activity of a human single-chain antibody to human immunodeficiency virus type 1 conserved gp41 epitope.

Authors:  I Legastelois; C Desgranges
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene.

Authors:  Danilo R Casimiro; Aimin Tang; Helen C Perry; Romnie S Long; Minchun Chen; Gwendolyn J Heidecker; Mary-Ellen Davies; Daniel C Freed; Natasha V Persaud; Sheri Dubey; Jeffrey G Smith; Diane Havlir; Douglas Richman; Michael A Chastain; Adam J Simon; Tong-Ming Fu; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists.

Authors:  A M Mhashilkar; D K Biswas; J LaVecchio; A B Pardee; W A Marasco
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

7.  Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex.

Authors:  Jason O'Donnell; Kenneth A Taylor; Michael S Chapman
Journal:  Virology       Date:  2009-01-13       Impact factor: 3.616

8.  A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice.

Authors:  Julia Steitz; Peter G Barlow; Jaber Hossain; Eun Kim; Kaori Okada; Tom Kenniston; Sheri Rea; Ruben O Donis; Andrea Gambotto
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

9.  Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Authors:  Danilo R Casimiro; Ling Chen; Tong-Ming Fu; Robert K Evans; Michael J Caulfield; Mary-Ellen Davies; Aimin Tang; Minchun Chen; Lingyi Huang; Virginia Harris; Daniel C Freed; Keith A Wilson; Sheri Dubey; De-Min Zhu; Denise Nawrocki; Henryk Mach; Robert Troutman; Lynne Isopi; Donna Williams; William Hurni; Zheng Xu; Jeffrey G Smith; Su Wang; Xu Liu; Liming Guan; Romnie Long; Wendy Trigona; Gwendolyn J Heidecker; Helen C Perry; Natasha Persaud; Timothy J Toner; Qin Su; Xiaoping Liang; Rima Youil; Michael Chastain; Andrew J Bett; David B Volkin; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 10.  Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics.

Authors:  Roland E Kontermann; Guy Ungerechts; Dirk M Nettelbeck
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.